Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
暂无分享,去创建一个
T. Ciuleanu | L. Stelmakh | S. Cicėnas | B. Klughammer | H. Johannsdottir | S. Miliauskas | C. Hillenbach | A. Grigorescu | E. González